文献速递血栓与止血

SELECT-D 试验:癌症相关静脉血栓栓塞治疗 12 个月结局

Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
PubMed 文献 · J Thromb Haemost · 2020-02-26

SELECT-D 试验在 6 个月抗凝治疗后,将 92 例活动性癌症伴残余深静脉血栓或索引肺栓塞患者随机分配至利伐沙班或安慰剂继续治疗 6 个月;12 个月时 VTE 复发率安慰剂组 14%、利伐沙班组 4%(HR 0.32,95%CI 0.06-1.58),大出血及临床相关非大出血在利伐沙班组分别为 5% 和 4%。

要点

  • 延长利伐沙班治疗可见 VTE 复发数值降低但未达统计学显著。
  • 利伐沙班组观察到大出血和临床相关非大出血事件。
  • 无残余深静脉血栓且无索引肺栓塞者复发风险低。

核心结论

  • SELECT-D 试验把握度不足,未能证实延长抗凝可显著降低 VTE 复发。
  • 无残余深静脉血栓和/或索引肺栓塞定义了低复发风险人群。

研究设计与样本

  • SELECT-D 为随机对照试验,第二随机阶段计划入组 300 例,因招募低提前关闭,实际随机 92 例。
  • 入组者为完成 6 个月试验治疗后仍有活动性癌症并伴残余深静脉血栓或索引肺栓塞的患者,随机接受额外 6 个月利伐沙班或安慰剂。

主要发现

  • 第二随机后 6 个月累积 VTE 复发率:安慰剂组 14%,利伐沙班组 4%(HR 0.32;95%CI 0.06-1.58)。
  • 大出血发生率:安慰剂组 0%,利伐沙班组 5%(95%CI 1-18)。
  • 临床相关非大出血发生率:安慰剂组 0%,利伐沙班组 4%(95%CI 1-17)。
  • 探索性分析中,46 例伴残余深静脉血栓或索引肺栓塞的安慰剂患者有 7 例(15%)复发 VTE,而无残余深静脉血栓的 35 例患者无复发(P = .03)。

临床怎么用

  • 对完成 6 个月抗凝的活动性癌症相关 VTE 患者,可评估残余深静脉血栓和索引肺栓塞以识别低复发风险者。
  • 延长利伐沙班治疗需权衡 VTE 复发降低与出血风险增加。

局限性

  • 第二随机阶段因招募低提前关闭,样本量仅 92 例,研究把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism (SELECT-D) trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared with dalteparin for treatment of acute VTE in cancer patients, at 6 months. Uncertainty remains around optimal duration of anticoagulation. OBJECTIVES: To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months. PATIENTS/METHODS: In SELECT-D, after 6 months of trial treatment for VTE, patients with active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE) were eligible for randomization to a further 6 months of rivaroxaban or placebo. Patients with no RDVT stopped anticoagulation. Primary outcome was VTE recurrence at 12 months. The second randomization closed prematurely because of low recruitment when 92 of the planned 300 patients were recruited. RESULTS: Ninety-two of 136 eligible patients were randomized to rivaroxaban or placebo. The cumulative VTE recurrence after 6 months from the second randomization was 14% with placebo and 4% with rivaroxaban (hazard ratio, 0.32; 95% confidence interval [CI], 0.06-1.58). The major and clinically relevant non-major bleeding rates were 0% and 0% with placebo; and 5% (95% CI, 1-18) and 4% (95% CI, 1-17) with rivaroxaban. In an exploratory analysis, 7 (15%) of 46 placebo patients with RDVT or an index PE experienced recurrent VTE compared to none in the 35 patients in the RDVT-negative cohort (P = .03). CONCLUSION: The SELECT-D trial was underpowered to detect a statistically significant reduction in recurrent VTE with extended anticoagulation. The absence of RDVT and/or index PE, defined a population at low risk of recurrence.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Marshall A, Levine M, Hill C, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). J Thromb Haemost. 2020. PMID: 31995662. doi:10.1111/jth.14752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。